ACP
CTIC

Acuta Capital Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Acuta Capital Partners’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-122,811
Closed -$2.9M – 88
2014
Q4 		$2.9M Buy
+122,811
New +$2.84M 1.96% 12

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Acuta Capital Partners's CTIC Position: Q1 2015 in Review

Acuta Capital Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2015, closing a stake of 122,811 shares — an estimated $2.9M sold.

Acuta Capital Partners first reported a position in CTIC in Q4 2014 and held it in 1 quarter. The position peaked at $2.9M in Q4 2014. 98 funds tracked by Wall St. Rank hold CTIC as of Q1 2015.

  • Acuta Capital Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 122,811 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2015, an estimated $2.9M.
  • Acuta Capital Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 1 quarter.
  • Acuta Capital Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.9M in Q4 2014.
  • 98 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.